Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision Biosciences, Inc. (DTIL) is a biotechnology innovator advancing the ARCUS genome editing platform for therapeutic and agricultural solutions. This page serves as the definitive source for verified company news, providing investors and industry professionals with timely updates on scientific milestones and corporate developments.
Access consolidated information on regulatory filings, research breakthroughs, and strategic partnerships directly impacting DTIL's position in the genome editing sector. Our curated feed includes earnings announcements, clinical trial updates, and technology licensing agreements, enabling informed analysis of the company's progress.
Key focus areas include ARCUS platform advancements in gene therapy programs, allogeneic CAR-T developments, and agricultural biotechnology applications. Users can track patent approvals, peer-reviewed study publications, and executive leadership updates through our chronologically organized news archive.
Bookmark this page for streamlined access to Precision Biosciences' official communications and third-party analysis. Check regularly for updates on how DTIL's precision gene editing technology continues to shape the future of genomic medicine and sustainable agriculture.
Precision BioSciences (Nasdaq: DTIL) announced it will present preclinical data on PBGENE-HBV, a program aimed at potentially eliminating hepatitis B virus (HBV). The oral presentation is scheduled for April 26, 2023, during the Global Hepatitis Summit in Paris, France. This program targets viral covalently closed circular DNA (cccDNA) for in vivo editing. The Chief Research Officer, Jeff Smith, emphasized the importance of specificity in gene editing to prevent off-target effects. Preclinical findings reveal that ARCUS nucleases achieve high on-target editing rates and reduce both intracellular cccDNA and hepatitis B surface antigen (HBsAg), without causing detectable translocations in human liver cells. This innovative approach supports the development of PBGENE-HBV as a potential cure for chronic HBV infections.
Precision BioSciences (DTIL) announced the selection of a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for treating Duchenne Muscular Dystrophy (DMD). This presentation will take place at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, from May 16-20, 2023. The PBGENE-DMD program utilizes ARCUS nucleases to excise a significant mutation area from the dystrophin gene, aiming to create a functional variant of the dystrophin protein. The oral presentation is scheduled for May 19, 2023, during the Late-breaking Abstracts 2 session, and public access to the abstract begins May 2, 2023. Precision BioSciences focuses on improving life through its novel gene editing platform, ARCUS, which is protected by a robust patent portfolio.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
